Drugs Controller General of India nod for Covaxin phase 3 trials

The SARS-CoV-2 strain was isolated in NIV, Pune and transferred to Bharat Biotech. The indigenous, inactivated vaccine is developed and manufactured in Bharat Biotech’s BSL-3 (Bio-Safety Level 3)

Hyderabad: Covaxin, the Covid-19 vaccine being developed by Bharat Biotech in collaboration with the Indian Council of Medical Research (ICMR) has been given approval for the third phase of clinical trials.

The SARS-CoV-2 strain was isolated in NIV, Pune and transferred to Bharat Biotech. The indigenous, inactivated vaccine is developed and manufactured in Bharat Biotech’s BSL-3 (Bio-Safety Level 3) High Containment facility located in Genome Valley, Hyderabad.

---

The DCGI granted permission to initiate Phase I & II human clinical trials in June this year, after the company submitted results generated from pre-clinical studies, demonstrating safety and immune response.

---

Now you can get handpicked stories from Telangana Today on Telegram everyday. Click the link to subscribe.

Click to follow Telangana Today Facebook page and Twitter .